Pharmacokinetic and pharmacodynamic study of NO-donating aspirin in F344 rats

International Journal of Oncology

Volumn 33, Issue 4, 2008, Pages 799-805

  Rao, Chinthalapally V ^a   Joseph, Stancy ^b   Gao, Li ^b   Patlolla, Jagan M R ^a   Choi, Chang In ^a   Kopelovich, Levy ^c   Steele, Vernon E ^c   Rigas, Basil ^b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; Chemoprevention; Nitric oxide donating aspirin; Prostaglandin E2; Thromboxane B2

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; DRUG METABOLITE; NITRIC OXIDE DONOR; PROSTAGLANDIN E2; SALICYLIC ACID; THROMBOXANE A2; THROMBOXANE B2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COLON MUCOSA; CONTROLLED STUDY; DIETARY INTAKE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG TISSUE LEVEL; FISCHER 344 RAT; MALE; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; TISSUE LEVEL;

ANIMAL FEED; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; COLON; DRUG EVALUATION, PRECLINICAL; EICOSANOIDS; MALE; NITRIC OXIDE; RATS; RATS, INBRED F344; SALICYLIC ACID; THROMBOXANE B2; TIME FACTORS;

EID: 54049099582     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo_00000067     Document Type: Article

References (15)

1. Rigas B: The use of nitric oxide-donating nonsteroidal antiinflammatory drugs in the chemoprevention of colorectal neoplasia. Curr Opin Gastroenterol 23: 55-59, 2007.
2. Williams JL, Nath N, Chen J, et al: Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-kappaB, and NO synthase 2 inhibition: implications for chemoprevention. Cancer Res 63: 7613-7618, 2003.
3. Rao CV, Reddy BS, Steele VE, et al: Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets. Mol Cancer Ther 5: 1530-1538, 2006.
4. Samuelsson B, Morgenstern R and Jakobsson PJ: Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev 59: 207-224, 2007.
5. Chell S, Kaidi A, Williams AC and Paraskeva C: Mediators of PGE2 synthesis and signalling downstream of COX-2 represent potential targets for the prevention/treatment of colorectal cancer. Biochim Biophys Acta 1766: 104-119, 2006.
6. Flavahan NA: Balancing prostanoid activity in the human vascular system. Trends Pharmacol Sci 28: 106-110, 2007.
7. Carini M, Aldini G, Orioli M and Maffei Facino R: In vitro metabolism of a nitroderivative of acetylsalicylic acid (NCX4016) by rat liver: LC and LC-MS studies. J Pharm Biomed Anal 29: 1061-1071, 2002.
8. Carini M, Aldini G, Orioli M, Piccoli A, Rossoni G and Maffei Facino R: Nitric oxide release and distribution following oral and intraperitoneal administration of nitroaspirin (NCX 4016) in the rat. Life Sci 74: 3291-3305, 2004.
9. Carini M, Aldini G, Orioli M, Piccoli A, Tocchetti P and Facino RM: Chemiluminescence and LC-MS/MS analyses for the study of nitric oxide release and distribution following oral administration of nitroaspirin (NCX 4016) in healthy volunteers. J Pharm Biomed Anal 35: 277-287, 2004.
10. Gao J, Kashfi K and Rigas B: In vitro metabolism of nitric oxide-donating aspirin: the effect of positional isomerism. J Pharmacol Exp Ther 312: 989-997, 2005.
11. Keeble JE and Moore PK: Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs. Br J Pharmacol 137: 295-310, 2002.
12. Rao CV, Rivenson A, Simi B and Reddy BS: Chemoprevention of colon carcinogenesis by dietarycurcumin, a naturally occurring plant phenolic compound. Cancer Res 55: 259-266, 1995.
13. Ukawa H, Yamakuni H, Kato S and Takeuchi K: Effects of cyclooxygenase-2 selective and nitric oxide-releasing non-steroidal antiinflammatory drugs on mucosal ulcerogenic and healing responses of the stomach. Dig Dis Sci 43: 2003-2011, 1998.
14. Yeh RK, Chen J, Williams JL, et al: NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property? Biochem Pharmacol 67: 2197-2205, 2004.
15. Kashfi K and Rigas B: Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention. Biochem Pharmacol 70: 969-986, 2005.